Events & Presentations
Upcoming Events
Jun 02 - Jun 06, 2023
- Abstract #2628: Phase I evaluation of PRGN-2009 alone and in combination with bintrafusp alfa in patients (pts) with recurrent/metastatic (R/M) HPV-associated cancers (HPV-C). Session Title: Developmental Therapeutics—Immunotherapy. Session Date and Time: June 3, 2023, 8:00 AM-11:00 AM CT.
- Abstract #5590: Phase 1/1b study of PRGN-3005 autologous UltraCAR-T cells manufactured overnight for infusion next day to advanced stage platinum resistant ovarian cancer patients. Session Title: Gynecologic Cancer. Session Date and Time: June 5, 2023, 1:15 PM-4:15 PM CT.
Jun 07, 2023 at 3:15 PM EDT
Rutul Shah, Chief Operating Officer of Precigen, will provide a company presentation on Wednesday, June 7, 2023 at 3:15 PM ET.
Boston, Massachusetts
Past Events
May 10, 2023 at 8:00 AM EDT
Precigen quarterly financial results and general business update.
Apr 17, 2023
at 9:00 AM - 12:30 PM EDT
An abstract titled, "Next generation UltraCAR-T® cells with intrinsic checkpoint inhibition and overnight manufacturing overcome suppressive tumor microenvironment leading to sustained antitumor activity," was selected for poster presentation.
Apr 04, 2023
at 10:45 AM - 11:15 AM EDT
Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a virtual fireside chat.
Apr 04, 2023 at 8:30 AM EDT
Precigen will host a conference call to provide business and clinical updates for recent announcements.
Mar 06, 2023 at 4:05 PM EST
Precigen fourth quarter and full year 2022 financial results and business updates.
Feb 28, 2023 at 7:00 AM EST
Helen Sabzevari, President and CEO of Precigen, will participate in virtual fireside chat, which will be available on-demand beginning at 7:00 AM ET on February 28.
Jan 24, 2023 at 4:30 PM EST
Precigen's virtual R&D day event showcased complete clinical trial safety and efficacy data from the Phase 1 dose escalation and expansion cohorts for the PRGN-2012 AdenoVerseTM immunotherapy in recurrent respiratory papillomatosis.
Jan 11, 2023 at 3:45 PM PST
Helen Sabzevari, PhD, President and CEO of Precigen, presents a corporate and clinical overview at the 41st annual J.P. Morgan Healthcare Conference.
Dec 12, 2022
at 6:00 PM - 8:00 PM CST
An abstract (Abstract# 4633) titled, "Phase 1/1b Safety Study of PRGN-3006 UltraCAR-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes," was presented as a poster presentation.
Dec 11, 2022
at 6:00 PM - 8:00 PM CST
An abstract (Abstract# 3334) titled, "A Phase1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients with Advanced Hematologic and Solid Tumor Malignancies," was presented as a trial-in-progress presentation.
Nov 09, 2022 at 4:30 PM EST
Precigen quarterly financial results and general business update. The conference call may be accessed by dialing 1-888-317-6003 (Domestic US), 1-866-284-3684 (Canada) or 1-412-317-6061 (International) and providing the participant access code 3010378. Participants are asked to dial in 10-15 minutes in advance of the scheduled call time to facilitate timely connection to the call.
Nov 08, 2022
Helen Sabzevari, PhD, Precigen President and CEO, to participate in Science of Business Fireside Chat.
Sep 07, 2022 at 11:35 AM EDT
Helen Sabzevari, PhD, President and CEO, participated in a fireside chat at the 2022 Wells Fargo Healthcare Conference in Boston, Massachusetts.
Aug 08, 2022 at 4:30 PM EDT
Precigen quarterly and half year financial results and general business update.
Jun 30, 2022 at 1:00 PM EDT
Helen Sabzevari, President and CEO of Precigen, participated in a virtual panel discussion titled, “Targeted T Cell Therapies, Including Autologous CAR T, TCR and More”.
May 24, 2022 at 7:00 AM EDT
Helen Sabzevari, President and CEO of Precigen, participated in a virtual fireside chat.
May 09, 2022 at 4:05 PM EDT
Precigen first quarter 2022 financial results.
Apr 12, 2022
at 9:00 AM - 12:30 PM CDT
An abstract titled, "Incorporation of intrinsic checkpoint blockade enhances functionality of multigenic autologous UltraCAR-T® cells manufactured using non-viral gene delivery and rapid manufacturing process," was presented as a poster presentation.